scispace - formally typeset
C

C. Guidali

Researcher at University of Insubria

Publications -  14
Citations -  1762

C. Guidali is an academic researcher from University of Insubria. The author has contributed to research in topics: Prefrontal cortex & Endocannabinoid system. The author has an hindex of 12, co-authored 14 publications receiving 1596 citations.

Papers
More filters
Journal ArticleDOI

Chronic delta 9-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: behavioral and biochemical correlates.

TL;DR: The results suggest that heavy cannabis consumption in adolescence may induce subtle alterations in the emotional circuit in female rats, ending in depressive-like behavior, whereas male rats show altered sensitivity to rewarding stimuli.
Journal ArticleDOI

Role in Anxiety Behavior of the Endocannabinoid System in the Prefrontal Cortex

TL;DR: Findings support an anxiolytic role for physiological increases in AEA in the PFC, whereas more marked increases or decreases of this endocannabinoid might lead to an anxiogenic response due to TRPV1 stimulation or the lack of CB1 activation, respectively.
Journal ArticleDOI

Changes in hippocampal morphology and neuroplasticity induced by adolescent THC treatment are associated with cognitive impairment in adulthood.

TL;DR: The data suggest that THC pretreated rats may establish less synaptic contacts and/or less efficient synaptic connections throughout the hippocampus and this could represent the molecular underpinning of the cognitive deficit induced by adolescent THC treatment.
Journal ArticleDOI

CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour.

TL;DR: The results suggest that while a mild activation of CB1 receptors in the prefrontal cortex and ventral hippocampus attenuates anxiety, a slight CB1 receptor stimulation in the amygdala results in an anxiogenic-like response.
Journal ArticleDOI

The endocannabinoid system and psychiatric disorders.

TL;DR: SR141716A and cannabidiol show the most constant antipsychotic properties in dopamine- and glutamate-based models of schizophrenia, with profiles similar to an atypical antipsychotics drug.